Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-04-11
2006-04-11
Weber, Jon (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S012200, C514S016700, C530S311000, C530S328000
Reexamination Certificate
active
07026289
ABSTRACT:
The present invention relates to a method of treating hyperlipidemia and to reducing triacylglycerols, glycerol and cholesterol in a patient. The method includes the step of administering a therapeutically effective amount of a type-5 selective somatostatin agonist to said patient. A pharmaceutical composition comprises said agonist and such product is used in the preparation of the composition for use in treating hyperlipidemia or reducing triacylglycerols, glycerol and cholesterol in a patient's body.
REFERENCES:
patent: 4133782 (1979-01-01), Vale, Jr. et al.
patent: 4146612 (1979-03-01), Veber
patent: 4190575 (1980-02-01), Sarantakis
patent: 4190648 (1980-02-01), Veber
patent: 4209426 (1980-06-01), Sarantakis
patent: 4211693 (1980-07-01), Rivier et al.
patent: 4215039 (1980-07-01), Sarantakis
patent: 4224199 (1980-09-01), Meyers et al.
patent: 4235886 (1980-11-01), Freidinger et al.
patent: 4238481 (1980-12-01), Rink et al.
patent: 4261885 (1981-04-01), Sakakibara et al.
patent: 4282143 (1981-08-01), Sarantakis
patent: 4291022 (1981-09-01), Sandrin et al.
patent: 4310518 (1982-01-01), Freidinger et al.
patent: 4316890 (1982-02-01), Kamber et al.
patent: 4328214 (1982-05-01), Rink et al.
patent: 4358439 (1982-11-01), Sieber et al.
patent: 4360516 (1982-11-01), Freidinger et al.
patent: 4369179 (1983-01-01), Rink et al.
patent: 4395403 (1983-07-01), Bauer et al.
patent: 4435385 (1984-03-01), Bauer et al.
patent: 4485101 (1984-11-01), Coy et al.
patent: 4486415 (1984-12-01), Freidinger
patent: 4522813 (1985-06-01), Nutt
patent: 4585755 (1986-04-01), Morgan et al.
patent: 4603120 (1986-07-01), Kamber
patent: 4650787 (1987-03-01), Schally et al.
patent: 4684620 (1987-08-01), Hurby et al.
patent: 4725577 (1988-02-01), Schally et al.
patent: 4728638 (1988-03-01), Bauer et al.
patent: 4853371 (1989-08-01), Coy et al.
patent: 4871717 (1989-10-01), Coy et al.
patent: 4904642 (1990-02-01), Coy et al.
patent: 5506339 (1996-04-01), Coy et al.
patent: 5708135 (1998-01-01), Coy et al.
patent: 5763200 (1998-06-01), Dunmore et al.
patent: 6004928 (1999-12-01), Cawthorne et al.
patent: 0 030 920 (1981-06-01), None
patent: 0 083 305 (1983-07-01), None
patent: 0 203 031 (1986-11-01), None
patent: 0 329 295 (1989-08-01), None
patent: 0 363 589 (1990-04-01), None
patent: 0 389 180 (1990-09-01), None
patent: 0 395 417 (1990-10-01), None
patent: 0 505 680 (1992-09-01), None
patent: 2 095 261 (1982-09-01), None
patent: 88/02756 (1988-04-01), None
patent: 88/05052 (1988-07-01), None
patent: 90/12811 (1990-11-01), None
patent: 91/09056 (1991-06-01), None
patent: 91/18016 (1991-11-01), None
patent: WO 96/35950 (1996-11-01), None
patent: WO9635950 (1996-11-01), None
patent: 97/01579 (1997-01-01), None
patent: WO9711962 (1997-04-01), None
patent: WO9810786 (1998-03-01), None
Moller et al., Clin. Science, vol. 75, pp. 345-350, 1988.
Ginsberg, et al., “Effect of Somatostatin-induced Suppression of Postprndial Insulin Response upon the Hypertriglyceridemia Associated with a High Carbohydrate Diet,” 1982, J. Clinical Invest. 70:1225-1233.
Pointner, H., et al., “Somatostatin Inhibits the Increase of Serum Triglyceride Concentration Following a Test Meal,” 1976, Scan. J. Gastroenterology 2:51.
Bruno, J., et al., “Molecular cloning and functional expression of a brain-specific somatostatin receptor,” 1992, Proc. Nat. Acad. Sci., 89:11151-11155.
Cohen, et al., “Effects of octreotide on lipid metabolism in acromegaly,” 1992, Hrom. Metab. Res., 24:397-400.
Davenport, et al., “Somatostatin type 5 receptors mediate the inhibitory action of somatostatin on insulin secretion in zucker fatty rat perfused pancreas,” 1995, Diabetologia, 38 (supp 01) :A106, abs. No. 410.
Fukushima, et al., “Effect of simultaneous infusion of a somatostatin analogue, insulin and glucose on serum triglycerides and blood glucose levels in man,” 1985, Endocinol. Japon., 32 (2) :241-248.
Horvath, A., et al., “Conformations of somatostatin analogues having antitumor activity,” 1992, Peptides, p533-534.
James, et al., “Carbohydrate tolerance and serum lipids in acromegaly before and during treatment with high dose octreotide,” 1991, Diabetic Medicine, 8:517-523.
Martin, et al., “Effect of a zinc phosphate suspension of a long-acting somatostatin analog on postprandial plasma glucose, triglyceride and glucagons concentration in alloxan diabetic dogs,” 1984, Life Sciences, 35:2627-2633.
Nakabayshi, et al., “Effect of somatostatin on the flow rate and triglyceride levels of thoracic duct lymph in normal and vagotomized dogs,” 1981, Diabetes, 30:440-445.
Van Binst, G., et al., “Backbone modifications in somatostatin analogues: Relation between conformation and activity,” 1992, Peptide Research, 5(1) :8-13.
Cawthorne Michael Anthony
Liu Yong-Ling
Sennitt Matthew V.
Feeney Alan F.
Fish & Richardson
Mohamed Abdel A.
Morrill Brian R.
Societe de Conseils de Recherches et d'Applications Scientifique
LandOfFree
Method and compositions for treating hyperlipidemia and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method and compositions for treating hyperlipidemia and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and compositions for treating hyperlipidemia and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3526941